KRAS and neoplasm: Longitudinal examination of KRAS mutated ctDNA, as a proxy for tumor burden and chemotherapy resistance, has been compared to the clinically established serum marker carbohydrate antigen 19 − 9 (CA19-9) and imaging data, with promising results10,13–15.